Pulse Biosciences Shares Climb On Application for Percutaneous Electrode Review
By Sabela Ojea
Shares of Pulse Biosciences jumped on Tuesday after the company said that it submitted a Food and Drug Administration premarket application for its CellFX nsPFA percutaneous electrode.
Shares were recently up 15% at $7.19. The stock has surged 315% in the past twelve months.
Once the 510(k) application has been accepted, the FDA will conduct its review and may request additional information from the company based on that review, the immuno-oncology company developing an oncolytic electroceutical therapy said.
The FDA's guidance suggests the goal is to complete the 510(k) substantive review within 90 calendar days, Pulse Biosciences said.
"We look forward to collaborating with the FDA throughout the review process," Chief Executive Kevin Danahy said.
The 510(k) program accounts for most new medical devices the FDA reviews to reasonably assure their safety and effectiveness, according to the FDA's website.
CellFX nsPFA is designed for non-cardiac applications.
Write to Sabela Ojea at sabela.ojea@wsj.com; @sabelaojeaguix
(END) Dow Jones Newswires
November 21, 2023 12:14 ET (17:14 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.-
5 Things We Learned From the Q1 Earnings Season
-
After Earnings, Is Palantir Stock a Buy, a Sell, or Fairly Valued?
-
What’s Happening In the Markets This Week
-
Can the Fed Declare Victory on Inflation?
-
After Earnings, Is Coinbase Stock a Buy, a Sell, or Fairly Valued?
-
After Earnings, Is Albemarle Stock a Buy, a Sell, or Fairly Valued?
-
Is ServiceNow Stock a Buy After Earnings and Its Investor Day?
-
3 Stocks to Buy and 3 Stocks to Sell After Earnings
-
Today’s Market Volatility Could Provide Tomorrow’s Opportunities
-
40 of the Best Investment Picks
-
Tech Stock Dividends Are Changing the Face of Dividend Growth Investing
-
Roblox Earnings: Weakening Engagement Has Weighed On Growth
-
The Best Gaming Stocks to Buy
-
Energy Transfer Earnings: M&A Drives Guidance Increase In Solid Quarter
-
The Best Healthcare Stocks to Buy
-
Going Into Earnings, Is Home Depot Stock a Buy, a Sell, or Fairly Valued?